Company profile - Aberdeen Asian income fund feature image - 28062019- JPGmoney & pens

Gathering portfolio momentum

Invesco Asia Trust 14 June 2016 Review

Imperial Innovations

Gathering portfolio momentum

Portfolio overview

Pharma & biotech

14 June 2016

Price

430.00p

Market cap

£693m

Net cash (£m) at 31 January 2016 including post period £97m net equity issue.

189

Shares in issue

161.2m

Free float

9%

Code

IVO

Primary exchange

AIM

Secondary exchange

N/A

Share price performance

%

1m

3m

12m

Abs

1.8

3.6

(7.5)

Rel (local)

3.1

4.9

2.9

52-week high/low

525.00p

341.25p

Business description

Imperial Innovations is a technology transfer, incubation and venture investment company. It invests in ventures from Imperial College London, Cambridge and Oxford universities and UCL. Over 90% of its portfolio value is in 20 companies, with most (c 77%) of its investments in healthcare.

Next events

Circassia: Cat-SPIRE data

Q216

FY16 results

October

CellMedica: Phase II CITADEL data

2016/17

PsiOxus Phase I EnAd data (SPICE and OCTAVE)

2017

Analysts

Lala Gregorek

+44 (0)20 3681 2527

Daniel Wilkinson

+44 (0)20 3077 5734

Imperial Innovations is a research client of Edison Investment Research Limited

The breadth and depth of Imperial Innovations’ investment portfolio was showcased at its Capital Markets Day, with a focus on six companies. Investor focus is keenly on Circassia’s impending CAT-SPIRE Phase III results, anticipated this quarter. Circassia represented c 22% of portfolio NAV at end-HY16, hence this binary event will affect near-term portfolio NAV. Nevertheless, with portfolio momentum gathering and a number of material near-term milestones drawing nearer, the potential for valuation creation beyond Circassia is becoming more visible.

Year end

Net portfolio value (£m)*

Cash**

(£m)

Net fair value gain (£m)

Net asset value (£m)

NAV/share (p)

DPS

(p)

07/14

252.0

176.5

40.5

404.8

295.1

0.0

07/15

327.2

128.1

21.3

420.1

306.3

0.0

07/16e

404.1

142.6

6.9

515.2

320.6

0.0

07/17e

489.1

88.8

15.0

519.5

323.3

0.0

Note: * Net value, excludes provisions. **Cash, cash equivalents and short-term investments.

Capital markets day: Highlighting portfolio strength

Four of Innovations’ top 10 portfolio companies (Nexeon, PsiOxus, CellMedica and Mission Therapeutics) and two ‘rising stars’ presented (Kesios and Econic Technologies), giving further insight into their recent progress, strategy, upcoming newsflow and management strength. These companies collectively represent c 28% of portfolio value at end-January, a similar weighting to Circassia. Material near-term milestones mean there is potential for future valuation uplift, which longer term may mean they overtake Circassia’s contribution to overall portfolio value.

Investment momentum in a maturing portfolio

With £91.6m of cash at end-January 2016, a £100m equity issue in February 2016, and the currently undrawn second £50m EIB loan, Innovations has sufficient funds (c £239m) to support its accelerating investment strategy by putting increasing capital to work in an ever-diversifying portfolio. To date in FY16, c £50m has been committed; we estimate £70m in portfolio investments for the full year. Momentum in and increasing maturity of the unquoted portfolio is shown by the number and size of recent funding rounds led by Innovations. These include £19m for Kesios, £60m for Mission Therapeutics, £30m for Nexeon, £31.5m for Inivata and £6.2m for FeatureSpace. They highlight the wider belief in the potential of these companies shared by the respective investment syndicates.

Valuation: Prospects underpin NAV premium

Innovations’ shares trade at a c 34% premium to our estimated FY16e NAV of 321p/share (at 31 July 2016). We believe this is a relatively modest premium based on historical performance and the prospect of significant value uplifts over the next few years as a result of investment across a range of maturing unquoted companies, which have the prospect of revaluations of their carrying value and upcoming catalysts.

Investment summary

Tech commercialisation and venture investment company

Imperial Innovations is a UK-based technology commercialisation and investment company. As at 31 January 2016, it had a portfolio of 105 investments in spin-out companies in the healthcare (therapeutics, medtech and devices), engineering and materials and ICT/digital sectors. These companies are spin outs from the UK’s leading academic centres within the so-called ‘golden triangle’ between London, Oxford and Cambridge (in the UK) and include Imperial College London (ICL), Cambridge University, Oxford University and University College London (UCL). In 2016, closer ties were forged with Cambridge University, ICL and UCL through participation in the £40m Apollo Therapeutics Fund and the £50m UCL Technology Fund. Innovations was founded in 1986 as the technology transfer office for ICL and was later itself spun out and subsequently admitted to AIM in 2006. It has raised a total of £346m in equity to date. Since listing in 2006, Innovations has invested a total of £264.3m across its portfolio companies, which have now collectively raised more than £1.3bn. Co-investors in the therapeutics portfolio are typically tier 1 institutions or VCs backed by big pharma or A-list funds.

Valuation: Uplift potential supports long-term NAV premium

Innovations’ shares (at 430p) currently trade at a c 34% premium to our estimated end-FY16 (31 July 2016) NAV of 321p/share. Innovations has historically traded at a premium to NAV, which can be ascribed to the unrecognised value of its portfolio (mostly private companies that are typically valued at cost or last financing round) and its access to innovative and disruptive technologies emerging from Imperial College and other leading UK universities (Oxford, Cambridge and UCL). We believe this premium is fully justified, based on strong historical portfolio performance and the prospect of significant uplift in the next couple of years from its maturing portfolio, including those companies that presented at Innovations’ capital markets event. We also expect that the funding rounds secured so far during financial H216 (Mission Therapeutics, Nexeon and FeatureSpace) will prompt a revaluation of the carrying value of these companies. Assuming some portfolio companies are successful in delivering on their near-term strategic objectives (eg, positive clinical data, deals, pipeline development, etc) then we would expect portfolio value to significantly outstrip investment. Ultimately this determines the return on investment for both Innovations and Innovations investors.

Sensitivities: Circassia data a near-term swing factor

The investment case rests on the success of Innovations’ investment strategy, in particular its ability to achieve increases in portfolio value (and hence NAV) over and above net new investment. The company is exposed to the business success of its larger portfolio holdings, especially for its publicly listed companies. With the carrying values of these companies marked to market at each financial period end, share price performance (particularly Circassia, which accounted for 22% of the total portfolio value at end-January 2016) may significantly affect the total portfolio value, positively or negatively: the upcoming results of the Circassia Phase III Cat-SPIRE study are likely to have a significant impact on reported FY16 portfolio NAV (end-July 2016).

Financials: Well funded to support investment strategy

With £91.6m of cash at end-January 2016, a £100m equity issue in February 2016 and the currently undrawn second £50m EIB loan, Innovations has sufficient funds to support its accelerating investment strategy (c £239m). Approximately £50m has been committed to date in FY16; we estimate £70m in portfolio investments for the full year. Innovations’ investment is steadily increasing with gross £60.8m invested in FY15 and £32.8m in FY14. We continue to predict a similar portfolio investment rate of £70m in FY17.

Portfolio momentum gathers beyond Circassia

Circassia’s upcoming Phase III Cat-SPIRE read out is a key focus for investors. While Circassia is the largest single component of Innovations’ portfolio (21.8% share with a net carrying value of £77.5m), the remaining 78.2% has the potential for significant value creation and is a vital part of Innovations future. Nevertheless, the Cat-SPIRE data coupled to Innovations’ limited free-float (c 10%) means that this binary outcome will inevitably have a significant impact on both Circassia and therefore Innovations’ share prices and investor sentiment in the near term (Exhibit 1).

Exhibit 1: Near-term implications from the two scenarios following Phase III Cat-SPIRE result

Positive Cat-SPIRE

Negative Cat-SPIRE

Circassia

Share price appreciation/valuation uplift

Significant value inflection point:

De-risks allergy pipeline and Toleromune platform

Commercialisation pathway/timelines for cat allergy programme becomes clearer

Other assets provide diversification and potential for further value creation

Fall in share price

Phase III grass allergy programme becomes lead allergy asset

Possible negative read through to platform/other allergy assets

Downside protection from diversified portfolio (particle engineering technology and asthma/COPD assets)

Buying opportunity for investors interested in non-allergy assets

Imperial Innovations

Share price appreciation

NAV uplift = the relative increase in Circassia share price between 31 January 2016 and 31 July 2016

Circassia represents a greater proportion of the portfolio:

When/whether to take profits/sell down to diversify portfolio vs

Potential to further benefit from impending cat allergy programme commercialisation

Circassia provides an exemplar for Innovations value creation investment approach

Fall in share price

NAV decrease = the relative decrease in Circassia share price between 31 January 2016 and 31 July 2016

Circassia represents a smaller proportion of the portfolio

Downside protection from:

Other Circassia pipeline assets and technology platforms

Other companies in Innovations portfolio

Buying opportunity for investors interested in other portfolio investments

Source: Edison Investment Research

Longer term, however, there is significant potential for value creation from Innovations unquoted portfolio, especially as a number of maturing ‘accelerated growth’ companies approach important catalysts. As of 31 January 2016, the unquoted portfolio was valued at £255.1m (vs £220.4m at 31 July 2015), with the quoted portfolio valued at £100.0m (vs £106.8m). Achieving technical, clinical and commercial milestones should prompt greater valuation uplifts in the future, while other mechanisms for unlocking unquoted portfolio value include IPOs or trade sales.

Momentum in and increasing maturity of the unquoted portfolio is evidenced by the number and size of recent funding rounds that Innovations has led. These include £19m for Kesios, £60m for Mission Therapeutics, £30m for Nexeon, £31.5m for Inivata and £6.2m for FeatureSpace. This also highlights the wider belief in the potential of these companies shared by the respective investment syndicates. Management from the first three companies presented at the recent Capital Market’s Day; we profile these and the other presenting companies below.

Capital markets overview

Innovations’ first Capital Markets Day in May 2016 provided the opportunity to showcase a number of its unquoted portfolio companies, including both established companies (Nexeon, PsiOxus, CellMedica and Mission Therapeutics) as well as more newly created ‘rising stars’ (Kesios and Econic Technologies). These companies collectively represent c 28% of the Innovations portfolio at end-January 2016 and, as such, had a similar portfolio weighting to Circassia. However, with material near-term milestones approaching for a number of these companies, there is significant potential for future valuation uplift, so that, together they could make a greater contribution to overall Innovations portfolio value than Circassia in the mid-term.

A common theme across the presentations was that Innovations’ involvement is not limited to providing funding to build high-quality companies, but also to supporting technology development and building highly skilled management teams. These world-class internationally experienced management teams consist of individuals with the right scientific and commercial acumen to develop and grow their respective companies with the aim of creating substantial value.

The fact that a number of important value inflection points are approaching for these portfolio companies (Exhibit 2) is of particular importance as, while the quoted portfolio is simply marked to market value, a substantial portion (c 83%) of the unquoted portfolio is valued at cost or last funding round, with a much smaller, albeit growing amount of value (c 14%) attributed to the last funding round and adjusted for milestones and impairments. As of 31 January 2016, the carrying value of the six presenting companies was c 1.58x the cumulative cash invested. Consequently, additional investment (such as the recent funding rounds for Nexeon and Mission Therapeutics) and the positive outcome of key catalysts have the potential to unlock hidden value.

Exhibit 2: Companies present at the Capital Markets Day

Company

Carrying value

IVO stake (%)

Description

Next newsflow/catalyst

Nexeon

34.09**

39.3**

Battery and licensing silicon anodes for next generation lithium-ion (Li-ion) batteries; consumer product/electric vehicle markets.

Ongoing technology development.

Securing a new joint development agreement.

Opening of lab in Japan.

PsiOxus Therapeutics

22.62

27.9

Developing novel therapies for cancer-related diseases: an oncolytic virus Enadenotucirev (enAd or ColoAd1) for solid tumours, AbEnAd (antibody-armed-Enadenotucirev) and the T-SIGn tumour specific delivery platform.

Phase I SPICE trial (EnAd + pembrolizumab in metastatic colorectal cancer): results expected 2017.

Phase I OCTAVE trial (EnAd + paclitaxel in ovarian cancer): results expected 2017.

Develop NG-348 (lead T-SIGn programme) through preclinical studies; into clinic in 2017.

Cell Medica

21.04

27.0

Developing T-cell immunotherapy for treatment of virally associated cancer and viral infection post-bone marrow transplant. Cytovir CMV is available in the UK. Lead cancer immunotherapy product is CMD-003.

CMD-003 Phase II CITADEL data: end 2016/early 2017.

CMD-003 CIVIC label expansion trial initiation 2016; data update in 2017.

Expansion of oncology pipeline: Phase I start of CMD-004 (HPV-related cancer) in 2017; Phase I start of first of CAR and TCR-modified targeted cancer programmes in 2018/19.

Mission Therapeutics

10.12*

21.2*

Developing cancer therapeutics targeting deubiquitylating enzymes (DNA damage response).

Start of IND track candidate process late-2016 (USP30) and early 2017 (USP7).

Phase I start: end-2017 (USP30) and 2018 (USP7).

Econic Technologies

6.2

56.1

Developing novel catalytic processes for polymer manufacture using waste carbon dioxide as feedstock.

Progress with customer process and development/catalyst scale up in 2016.

First catalyst sales and customer scale up in 2017.

First product launch in 2019.

Kesios Therapeutics

5.7

42.0

Developing therapeutics for multiple myeloma and other haematological cancers based on a novel NFκB signalling pathway drug target.

KES-001 Phase I multiple myeloma start Q2/Q316.

Start of Phase I combination trials in 2017.

Source: Edison Investment Research, Imperial Innovations. Note: Net investment carrying value, cash invested and % ownership at 31 January 2016. Carrying values reflect the net fair value of the investment (gross value less attributable revenue-sharing obligation). *Includes £4.1m fair value gain reflecting the £60m tranched funding round announced in February 2016. **Prior to May 2016 funding round; IVO stake post-money was reported as 33.7%.

Nexeon

Nexeon was founded in 2005 with an aim to develop next generation batteries built on silicon anode technology. Innovations reported cumulative investment £22.4m as of 31 January representing a net carrying value of £34.1m. Post period, Nexeon announced a £30m funding round in May in which Innovations committed £5.0m. Innovations’ stake in Nexeon, including the most recent funding round, was reported at 33.7%. Nexeon has raised a total of £85m in equity.

Nexeon has been led by CEO Dr Scott Brown since June 2009. His prior senior management roles at Cambridge Display Technology included responsibilities for commercial and R&D activities; he also spent time in Japan working closely with some of the leading Asian electronic companies. In August 2013, Tsuyonobu Hatazawa joined Nexeon in 2013 from Sony after a long career in battery development; he is now directing Nexeon technical strategy as chief technology officer. An experienced scientific advisory board strengthens Nexeon’s battery sector expertise.

The new funds raised in May will enable Nexeon to both acquire IP complementary technology and begin designing a larger manufacturing plant. A new lab in Japan also aided by the recent funding round will enable Nexeon to be closer to its key customers and partners and facilitate access to local battery expertise, while a 20 tonne manufacturing plant in Oxfordshire will allow delivery in the quantities that are required.

Unlike most current lithium batteries, which use carbon anodes, Nexeon uses silicon. Silicon anodes allow for approximately 11 times the increased gravimetric battery capacity (theoretical capacity of 4,212mAh/g) of carbon anodes (theoretical capacity of 372mAh/g); however, they generally have poor life cycles caused by mechanical failure. These result from large volume changes (often up to 400%) that occur when the batteries are charged and drained. Nexeon states that it has overcome this problem, allowing for both increased capacity over carbon anode technology as well as similar battery lifespan. This volumetric increase needs to be considered in battery design; as such the volumetric energy density is a still impressive but more modest increase, typically representing a three-fold improvement over lithium carbon batteries.

Nexeon believes it has a market leading technology that is, amongst other things, compatible with current manufacturing processes and demonstrates increased capacity per weight/volume. However, little is publically disclosed about Nexeon’s current batteries including their capacity and lifespan. As the company continues to grow, more visibility on its technology may occur as Nexeon looks to position itself as a market leader.

Of importance is Nexeon’s approach to manufacturing. The speed of adaptation of innovative technology can often rely on how well it fits with current standards and practices. Nexeon has a ‘drop in’ (batteries can be manufactured with minimal change to existing techniques) approach to its manufacturing that it believes minimises disruption. Additionally the batteries are designed to easily ‘drop in’ to products. One way this is achieved is by having them operate at the same voltage as existing lithium ion batteries. This allows them to be used with existing technology without the need for modifications.

Improved battery technology is largely seen as one of the main technological challenges facing both the automotive and mobile phone sectors. Most advancements in battery life have been incremental in the last decade and the majority are a result of better software rather hardware. As such, there is a major need for new higher capacity battery technology and many companies are competing to become the market leader. Arguably Tesla Motors (TSLA) is leading the way and has diversified into power cells for both business and homes. The construction of its own gigafactory battery production plant will make them one of the global leaders in battery production and highlights the growing global demand for higher capacity batteries. This increased awareness being generated by companies like Tesla is beneficial for Nexeon as it widens the audience of potential investors beyond what was, until recently, a niche market.

PsiOxus Therapeutics

PsiOxus Therapeutics is an immune-oncology company focused on oncolytic viruses. It was founded in 2010 in its present form, having been created by the combination of Imperial College-spin out Myotec Therapeutics with Hybrid BioSystems. It has, to date, raised £45.7m with the most recent funding round being a £25m Series C in May 2015. Innovations has invested £13.7m which had a last reported net carrying value of £22.6m and represented a 27.9% of holding.

John Beadle has been CEO of PsiOxus since inception, having been CEO of both progenitor companies. He was previously co-founder and chief medical officer of PowderMed, which was subsequently acquired by Pfizer for over $300m in 2006. Prior to PowderMed, he held roles at PowderJect, Pfizer and GlaxoSmithKline where he was most recently VP, Global Medical Operations. PsiOxus’ management was further strengthened by the appointment of Paolo Paoletti in January 2016. Dr Paoletti is CEO of another Innovations portfolio company, Kesios Therapeutics, and was previously president, GSK oncology and VP, clinical development at Lilly Oncology.

Enadenotucirev (EnAd), PsiOxus’ lead programme, is an oncolytic virus that was generated from an adenovirus library that underwent multiple rounds of selection against tumour cells. Viruses that killed the aforementioned tumour cells were then tested against healthy cells to check specificity. Viruses that demonstrated low healthy cell death were then chosen as a product candidate (EnAd). It can be delivered intravenously or by intra-tumoural injection and kill the cancer cells by lysis.

EnAd, formerly known as coloAd1, is being studied in four clinical trials in a variety of cancer indications. Data is available from a dose finding Phase I/II study (EVOLVE) and a Phase I mechanism of action study (MoA). Combination studies of EnAd with paclitaxel (OCTAVE study) and pembrolizumab (SPICE study) are ongoing. Results so far suggest that EnAd has a safety profile in line with other adeno-associated viruses with mostly grade 1 or 2 events while efficacy data at this stage is limited due to the early stage of results and limited patient numbers (data to date is from 10 patients in the MoA study and 15 patients in EVOLVE). Safety and initial efficacy data from OCTAVE and maximum tolerated dose data from SPICE are expected later this year, with clinical proof of concept in both studies expected to be achieved in 2017.

Exhibit 3: NG-348: Lead T-SIGn Therapy

Source: PsiOxus Therapeutics

EnAd appears to have a number of potential benefits over Amgen’s first-in-class oncolytic virus, Imglyic (talimoegne laherperivec or T-vec), which is approved for melanoma and was the rationale behind its $1bn acquisition of BioVex in 2011. These benefits include mode of administration, not being subject to the same manufacturing limitations, improved stability and potential for use in all epithelially derived tumours (but not melanoma or other neuroendocrine tumours).

PsiOxus also has a tumour specific delivery platform, T-SIGnTherapy, which underpins its next-generation pipeline. This includes a number of preclinical projects that are being designed to deliver immunotherapies to local tumour sites of action using variously cytokines, antibodies, T-cell activating ligands and combinations of the above. The lead T-SIGn programme is NG-348, a virus that modifies tumour cells to express a receptor that is recognised by a T-cell. It aims to be an off-the-shelf mass-produced product directed against solid tumours and is expected to enter the clinic in 2017.

Cell Medica

Founded in 2007, Cell Medica is focused on T-cell immunotherapies for immune reconstitution and immuno-oncology. To date they have raised £72m, of which £12.3m has been invested by Innovations (representing a carrying value of £21m at end-January 2016). Innovations holds a 27% interest in the company. The most recent capital raise was a £50m series B funding led by Innovations (which committed £15m) in November 2014.

Cell Medica has one marketed product, Cytovir CMV, which is indicated for the prophylaxis and treatment of CMV (cytomegalovirus) infections following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Cytovir CMV consists of anti-CMV T-cells, which are manufactured from the peripheral blood mononuclear cells of a matching healthy donor.

Cytovir CMV was studied in two clinical trials ASPECT and IMPACT. ASPECT involved two arms, which were randomised 2:1 in favour of the treatment arm. 35 patients were enrolled in the treatment arm with 18 withdrawals due to various factors mainly relating to existing GvHD (n=6) or insufficient starting material (n=8). A 109.1 +/- 42.5 fold increase in CMV specific cells for the treatment arm was observed compared with a 10.5 +/- 7.1 increase in the control arm (17 patients with six withdrawals). The IMPACT study demonstrated similar safety in the treatment arm as the control; while there were reduced CMV reactivations in the treatment arm, they were not statistically significant. Cytovir CMV is commercially available (pre-reimbursement) in the UK, Germany and Ireland; reimbursement is anticipated in 2017.

The second immune reconstitution programme, Cytovir ADV, is in development for the treatment of adenovirus (ADV) infections following an allo-HSCT. Cytovir consists of allogenic, expanded ADV specific T-cells. It is currently in an ongoing Phase I/II trial (ASPIRE); interim analysis reported complete adenovirus remission in all five patients who received treatment. Consultation with the EMA for scientific advice is planned in Q316.

Cell Medica’s immune-oncology pipeline is focused on viral and infection related cancers. The lead product candidate, CMD-003, consists of engineered T-cells that target cancer cells which express the oncogenic Epstein Barr virus (EBV). EBV is part of the Herpes family of viruses and by some estimates infects around 90% of the population. EBV was the first virus to be discovered to cause cancer and is now widely associated with a range of cancers. CMD-003 is being trialled across four indications, three of which are at the preclinical stage. The lead indication is EBV positive extranodal natural killer T cell lymphoma (ENKTCL), which is in a Phase II trial titled CITADEL.

CITADEL is a single-arm 35 patient Phase II trial for patients who have previously failed asparaginase-based chemotherapy or are high risk (regardless of chemotherapy status). Treatment involves two injections at days one and 15 with further injections at week eight, month three and month six for patients without clinical signs of disease progression at week eight. CITADEL enrolled its first patient in early 2015; initial data is expected towards end-2016 with completion expected in 2017. A similar product to CMD-003 is also under investigation in patients with a range of EBV+ lymphomas in the GRALE study at the Baylor School of Medicine; data updates are anticipated in 2016.

CMD-003 was given orphan drug status by the FDA in March 2015 for the treatment of EBV+ non-Hodgkin lymphomas. FDA Fast Track Status and European Orphan Designation may be achieved later this year. This would potentially allow for accelerated progression to market with possible BLA/MAA filings for ENKTCL in 2018/19.

Towards the end of 2016 we expect the initiation of label expansion studies for CMD-003 with the CIVIC trial. This will study CMD-003 in three additional indications: EBV+ Hodgkin’s lymphoma, EBV+ diffuse large B cell lymphoma and EBV+ post-transplant lympho-proliferative disease. Label expansion applications could be filed in 2022/2023. The expected completion of the CITADEL trial and data updates for CIVIC, both expected in 2017, will represent potential major value inflection points for Cell Medica. Additionally, progress is expected with the earlier-stage pipeline in 2017; in particular: (1) CMD-044 for HPV-related cancer, which has shown proof of concept in academic studies and will move into Phase I in 2017; and (2) CAR and TCR-modified targeted cancer programmes, of which the first should complete preclinical development in the same timeframe, ahead of possible Phase I start in 2018/19.

MISSION Therapeutics

Mission Therapeutics is a drug discovery and development company that was founded in 2011 by Professor Steve Jackson of the University of Cambridge. It is developing a pipeline of small molecule drugs focused around the ubiquitin pathway, particularly inhibitors of deubiquitylating enzymes (DUBS). Ubiquitin is a small protein that is found in the vast majority of tissues and is involved in numerous cellular processes, including DNA damage and cell proliferation, so the inhibition of these enzymes holds the potential to treat cancer and other unmet medical needs, including neurodegenerative disease, muscle wasting and infectious disease.

Since January 2015, Dr Anker Lundemose MD PhD has been CEO. He has extensive management experience, most recently having been CEO of Bionor Pharma and co-founder/CEO of Prosidion, and has also been involved in six biotech exits and IPOs. Mission’s founder and chief scientific officer, Professor Steve Jackson, has been part of the Gurdon Institute in Cambridge since 1991 and is the senior group leader as well as the head of Cancer Research UK’s laboratories. He also co-founded KuDOS Pharma, which was acquired by AstraZeneca in 2006 for £120m and was the originator of Lynparza (olaparib), the first PARP inhibitor, approved in 2014.

Mission has raised a total of £87m in venture associated capital, with £60m coming from a February 2016 Series C funding round. Innovations had invested £5.8m as of 31 January 2016 and made a further commitment for £11.3m in the February fund raise. This fresh financing allows Mission Therapeutics to accelerate the development of a series of first-in-class small molecule drug candidates, targeting specific DUBs, and advance their product candidates into the clinic. The two lead programmes, a potentially disease modifying USP30 inhibitor for Parkinson’s disease and a USP7 inhibitor for unspecified cancers, are expected to start their lead IND candidate selection process within the next 12-18 months.

The USP30 inhibitor for the treatment of neurodegeneration in Parkinson’s disease is believed to enhance mitophagy and will begin the IND track candidate process in late 2016. USP30 is a deubiquitylating enzyme that when overexpressed can block the degradation of damaged mitochondria through mitophagy. Defective mitophagy is believed to be linked to Parkinson’s disease; thus inhibition of USP30 may be beneficial in Parkinson’s disease by promoting mitochondrial clearance. Initiation of Phase I studies is planned around end-2017 to provide proof of principle for improving mitophagy in Parkinson’s disease patients in a sub-acute Phase Ib setting. There is potential for expansion of clinical studies into other neurodegenerative indications involving mitochondrial dysfunction (eg amylotropic lateral sclerosis, Huntington’s and Alzheimer’s diseases).

Their second lead candidate is a USP7 inhibitor for use within oncology that inhibits regulatory T-cells (Tregs). Its IND track candidate process is expected to start in H117. USP7 is known to be involved in several oncogenic pathways; of key interest is its ability to control the suppression of Tregs through regulation of Foxp3. Inhibition of USP7 decreases Treg suppression, which may be beneficial in a cancer setting as it has the potential turn non-responsive immune-oncology patients into responders. Hence Mission plans to combine its USP7 inhibition with immune checkpoint inhibitors. Initiation of Phase I is planned for 2018.

Mission’s strong cash balance post-Series C should enable it to deliver Phase I results for its two lead programmes, which if successful will provide validation to their wider platform. Deubiquitylating enzyme-based therapies are in their infancy and while they hold promise, Phase I results will prove the first litmus test for the company and more broadly the field.

Econic Technologies

Econics Technologies’ platform uses proprietary catalyst technology to develop polymers that partly comprise carbon dioxide (CO2) displacing more expensive petrochemical feedstocks. It was founded in 2011 as a spin out from the Chemistry Department of Imperial College based on technology co-invented by Prof Charlotte Williams (CSO) and Dr Mike Kember (head of research & IP). In 2014 Dr Rowena Sellens joined the company as CEO; she was most recently general manager EMEA at Lucite International after having held a number of previous roles within the same company. To date, Innovations has invested £4.4m with a carrying value of £6.1m, representing a 56.1% shareholding.

Exhibit 4: Econic’s catalytic polymerisation process

Econic’s technology allows for the production of polymers from CO2 and epoxides; these are linked together by Econic’s catalysts and produce an alternating polymer chain (Exhibit 4), which can contain up to 43% CO2 by weight. This basic polymer structure is altered in length and endings to suit the required application. Currently this consists of two main technologies: low molecular weight (LMW) polycarbonate polyols and high molecular weight polycarbonates.

The core focus for Econic is LMW polycarbonate polyols, which are the main component used in the production of more complex polymers such as polyurethane. Polyurethane is used in an array of commercial products from footwear and mattresses to cars. The polyol market represents c 7% of the global plastics market and is, according to Econic, a $20bn market growing at over 5% pa.

A key feature of Econic’s catalyst technology is the reduced CO2 footprint it has vs conventional polymer products. The utilisation of CO2 within the polymers has a dual effect:

The polymer technology acts as a carbon capture system as CO2 that may have been directly released into the atmosphere is stored within the polymers (up to 43% by weight). For every one tonne of waste CO2 used, the generation of twice as much CO2 is avoided.

Existing technology uses raw petrochemical feedstock to make all repeat units of a polymer compared with approximately half needed for Econic’s polymers. Sourcing and using this raw material is extremely CO2 intensive as well as generally damaging to the environment.

Econic’s catalyst technology has both environmental benefits and economic benefits. In polymer production the main cost relates to the raw materials that are derived from petroleum. As nearly 50% of this raw material is replaced with cheaper CO2, overall costs should be significantly reduced. Thus it can be applied to both specialty markets (producing higher value product properties at reduced cost) and bulk markets (saving costs on both raw materials and the production process). Econic’s technology produces a uniform and consistent product under the same conditions as the original process and it also has a process advantage vs the competition (eg Covestro and Novomer). It is lower cost and also the only catalyst that can be retrofitted on to existing manufacturing assets.

The transition to commercialisation from development is underway. Econic has active programmes with six out of the 10 global polyol producers and is at the process and product development stage with two market leaders. Catalyst scale up is ongoing during 2016, with first catalyst sales (and therefore revenues) and customer scale up expected in 2017. Potential first product launch could be in 2019 with regular sales from established customers anticipated by the company by 2020.

Kesios Therapeutics

Kesios Therapeutics is a clinical stage drug development company focused on personalised medicine for multiple melanoma. It was founded in November 2015 as a spin out of the Department of Medicine at Imperial College having raised £19m in a Series A round. Of this £19m investment, £3.3m was invested by Innovations, which at end-January 2016 reported having a net carrying value of £5.7m. Innovations currently has a 42% shareholding.

Kesios has a highly experienced management team, which is led by CEO, Paolo Paoletti, who was previously the president of GSK oncology and the VP of clinical development at Lilly Oncology. The CMO, Jane Robertson, is a practising physician who was previously Executive Global Clinical Director (Oncology) at Astra Zeneca. Kesios was founded by Guido Franzosa MD,PhD, Menotti Ruvo, PhD and Laura Tornatore, PhD to develop and commercialise initial work at Imperial College London where Professor Franzosa is the head of the centre for signalling and inflammation, as well as professor and chair of signal transduction and inflammation.

Exhibit 5: A novel target in the NF-KB survival pathway in cancer

Source: Kesios Therapeutics

Kesios’s lead product candidate is KES-001, which has a novel target (GADD45β/MKK7) in NF-KB signalling pathway in cancer (Exhibit 5). KES-001 binds to the JNK kinase, MKK7, causing disruption of the GADD45β (an anti-apoptotic protein)/MKK7 complex that in turn disrupts the NF-KB survival pathway. The binding of GADD45β to MKK7 is an essential survival pathway of cancerous cells; hence inhibition of this should lead to an increase in cancer cell death.

Preclinical data presented at the Capital Markets Day demonstrates an increase in non-myeloma cell survival compared with bortezomib (a proteasome inhibitor marketed as Velcade) while retaining a similar decrease in cell survival for multiple myeloma plasma cells. This indicates a potential increased selectivity over the current treatment standard. KES-0001 (iv formulation) received IND clearance in March 2016 and is on track to begin a Phase I trial in Q2/Q316.

Initial trials will focus on supporting approval in fourth-line refractory multiple myeloma, targeting US and EU filing by early 2020. In parallel, formulation work will be underway for a second-generation subcutaneous/intramuscular controlled-release formulation. Phase I combination studies of KES-001 in myeloma patients with high GADD45β, targeting earlier lines of therapy, are expected to launch in 2017, before expanding into other haematological malignancies and solid tumours.

Sensitivities

Imperial Innovations’ investment case rests on the success of its investment strategy, in particular its ability to achieve increases in portfolio value (and hence NAV) over and above net new investment. The company is exposed to the business success of its larger portfolio holdings, especially as its investment portfolio includes three publicly listed companies within the top 10 valued assets. The share price performance of the public portfolio companies (particularly Circassia, which accounted for 21.8% of the total portfolio value at 31 January 2016) may affect the total portfolio value either negatively or positively, with the carrying values of these investments marked to market at each financial period end. The upcoming readout of the Circassia Phase III cat-SPIRE trial represents a key near-term binary event.

Imperial Innovations is also very tightly held, with four shareholders accounting for a total of 90% of the equity, including Invesco (39.8%), Woodford (20.0%), Imperial College (17.4%) and Lansdowne (12.9%). This contributes to limited free float (8.9%) in the stock, which may increase volatility even on low trading volumes.

Valuation

Imperial Innovations’ shares (at 430p) currently trade at a c 34% premium to our estimated FY16e NAV of 321p/share (at 31 July 2016), after adjusting for the February capital raise and disclosed portfolio performance. Innovations has historically traded at a premium to its NAV, which can be ascribed to the unrecognised value of its portfolio assets (many of which are valued at cost or the valuation of their last financing) and its technology pipeline agreement with Imperial College and collaborations with other leading UK universities (Oxford, Cambridge, UCL) and other research organisations (eg Babraham Institute). We note that the current premium remains substantially lower than the >50% premium typically observed over the last two years. We continue to ascribe this ongoing weakness in the wider stock market, which has had an impact on healthcare stocks in particular. This could now provide a more favourable entry point, particularly as Innovations seeks to accelerate investment into a maturing portfolio, with the caveat that the company is facing a key binary event in the coming weeks with the readout of the Circassia Cat-SPIRE trial.

We believe a premium is justified, based on the strong historical portfolio performance and the prospect of significant uplift in the next couple of years from a number portfolio companies, including those that presented at Innovations’ capital markets event. Assuming some of these companies are successful in delivering on their near-term strategic objectives (eg, positive clinical data, deals, pipeline development, etc) we would expect portfolio value to significantly outstrip the cash invested. Ultimately this will determine the return on investment for both Innovations in its portfolio and investors in Innovations’ shares.

Importantly, Innovations has substantial financial resources (c £239m) to make the required investment in its maturing portfolio companies, which could deliver significant returns in the long run.

Financials

As of 31 January 2016, Innovations’ portfolio consisted of 105 companies, with a net portfolio value of £355.1m (vs £327.2m at end FY15). The main contributor to the £27.9m portfolio uplift was investments of £27.5m across 17 companies (HY15: £22.4m in 13 companies). Unrealised fair value gains of £12.7m were largely offset by disposals of £0.1m and fair value losses of £12.2m.

The February 2016 capital raise, which grossed £100m (estimated £97.0m net) through the placing of 23.5m new shares at 425p, primarily to Innovations’ major institutional shareholders (Woodford 56%, Invesco 25%, Lansdowne 7%), significantly increased Innovations’ financial position. When added to the £91.6m held in cash at 31 January 2016 (as reported by Innovations) and the £50m EIB loan facility (currently undrawn), we estimate that Innovations has c £239m available for investment after the £27.5m invested in H1. This capital is being put to work at an increased rate; at HY16 results, Innovations confirmed that £38.9m had been invested. This included £27.5m during the period and £11.4m post period (Mission Therapeutics Series C round). Subsequently, Innovations has made further investment commitments in Inflowmatix (£1.8m), Nexeon (£5m) and FeatureSpace (£2.5m).

We maintain our assumption of an estimated £70m in portfolio investments in FY16 as Innovations’ investment rate continues at a higher level than prior years. We highlight that c £50m has been invested, or committed, so far in FY16 (since 1 August 2015), which compares to £60.8m invested during FY15 and £32.8m in FY14. We continue to predict a similar portfolio investment rate of £70m in FY17 and assume that £30m of the total £50m EIB loan is drawn-down in FY17. This second EIB loan was granted to Innovations in July 2015 and can be drawn in £10m minimum tranches until July 2017. We note that Innovations drew down the full £30m from its first EIB loan (in two £15m tranches in FY14 and FY15).

Our FY16 revenue forecast of £5.1m (revenues from licensing/royalties, services and corporate finance) is maintained in line with FY15 (£5.1m) at this stage.

With relatively stable operating expenses, Innovations’ profitability is dependent on the level of fair value gains/losses in specific periods taken through the P&L. Gains and losses are inherently difficult to predict. Our change in net fair value estimate for FY16 now reflects an estimated gain of £6.9m (vs a £4.25m loss previously); we have increased our fair value gain expectation from c £5m to £6.2m in H216 to reflect the £1.4m fair value gain that was crystallised by the sale of Stanmore Implants to Stryker in April. We continue to expect uplift in fair value as portfolio companies mature and progress. We expect that the substantial funding rounds secured so far during FY H216 by Mission Therapeutics, Nexeon and FeatureSpace will prompt a revaluation of the carrying value of these companies. The unquoted portfolio valued at cost or last funding round (83.3% of the unquoted portfolio at end-January), at last funding round adjusted for milestones or impairments (14.4%) or on a sales multiple (2.3%). However, the major swing factor remains the results of Circassia’s Cat-SPIRE Phase III study in Q216, which is likely to have a materially positive or negative impact on Innovations’ fair value for its holding. We continue to estimate a £15m fair value gain in FY17, although this could be conservative in the context of a maturing company portfolio approaching numerous important catalysts.

Exhibit 6: Financial summary

£'000s

2013

2014

2015

2016e

2017e

Year end 31 July

IFRS

IFRS

IFRS

IFRS

IFRS

PROFIT & LOSS

 

 

 

 

 

 

 

Revenue

 

 

3,290

3,636

5,099

5,101

5,226

Cost of sales

 

 

(788)

(1,005)

(1,769)

(1,696)

(1,759)

Gross profit

 

 

2,502

2,631

3,330

3,405

3,467

EBITDA

 

 

(6,940)

(8,385)

(8,223)

(10,581)

(11,219)

Operating profit (before GW and except.)

(6,972)

(8,418)

(8,237)

(10,595)

(11,233)

Fair value gains/losses

 

 

10,794

40,549

21,324

6,899

15,000

Impairments

 

 

(3,492)

0

0

0

0

Share-based payment

 

 

2,358

(4,821)

1,161

(550)

(1,500)

Operating profit

 

 

2,688

27,310

14,248

(4,246)

2,267

Net interest

 

 

1,072

106

817

348

(232)

Profit before tax (norm)

 

 

(5,900)

(8,312)

(7,420)

(10,246)

(11,465)

Profit before tax (FRS 3)

 

 

3,760

27,416

15,065

(3,897)

2,035

Tax

 

 

0

0

0

0

0

Profit after tax (norm)

 

 

(5,900)

(8,312)

(7,420)

(10,246)

(11,465)

Profit after tax (FRS 3)

 

 

3,760

27,416

15,065

(3,897)

2,035

 

 

 

 

 

 

 

 

Average number of shares outstanding (m)

 

81.2

102.4

136.2

148.9

160.7

EPS - normalised (p)

 

 

(7.3)

(8.1)

(5.4)

(6.9)

(7.1)

EPS - FRS 3 (p)

 

 

4.6

26.8

11.1

(2.6)

1.3

Dividend per share (p)

 

 

0.0

0.0

0.0

0.0

0.0

 

 

 

 

 

 

 

 

BALANCE SHEET

 

 

 

 

 

 

 

Fixed assets

 

 

188,261

258,327

333,936

411,162

496,174

Tangible assets

 

 

36

26

29

35

46

Intangible assets

 

 

0

0

0

0

0

Investment Portfolio

 

 

187,649

257,105

333,268

410,167

495,167

UCSF (University Challenge Seed Fund) investments

517

543

460

460

460

UCSF loans

 

 

0

0

0

0

0

Other

 

 

59

653

179

500

501

Financial asset

 

 

0

0

0

0

0

Current assets

 

 

67,130

177,800

130,506

145,033

91,226

Cash and cash equivalents

 

 

65,597

176,462

128,097

142,623

88,757

Financial asset

 

 

0

0

0

0

0

Accounts receivable, net

 

 

1,533

1,338

2,409

2,410

2,469

Current liabilities

 

 

(3,391)

(4,900)

(5,732)

(5,732)

(5,732)

Trade accounts payable

 

 

(3,391)

(4,900)

(4,232)

(4,232)

(4,232)

Short-term borrowings

 

 

0

0

(1,500)

(1,500)

(1,500)

Long-term liabilities

 

 

(21,542)

(26,445)

(38,639)

(35,245)

(62,123)

Long-term borrowings

 

 

(14,814)

(14,830)

(27,222)

(24,500)

(52,050)

UCSF

 

 

(605)

(640)

(666)

(666)

(666)

Provisions

 

 

(6,123)

(10,975)

(10,751)

(10,079)

(9,407)

Net assets

 

 

230,458

404,782

420,071

515,218

519,545

NAV/share (p)

 

 

231

295

306

321

323

 

 

 

 

 

 

 

 

CASH FLOW

 

 

 

 

 

 

 

Operating cash flow

 

 

(7,465)

(6,523)

(9,331)

(10,580)

(11,160)

Net Interest

 

 

921

44

875

348

(232)

Tax

 

 

0

0

0

0

0

Capex

 

 

(4)

(23)

(17)

(20)

(25)

Purchase of trade investments

 

 

(22,185)

(32,826)

(59,957)

(70,000)

(70,000)

Proceeds from sale of trade investments

 

 

396

3,370

7,179

0

0

Revenue share paid on asset realisations in trade investments

 

 

(172)

0

(989)

0

0

Equity financing

 

 

36,990

146,823

0

97,500

0

Short term liquidity investments

 

 

(1,581)

0

0

0

0

Net cash flow

 

 

6,900

110,865

(62,240)

17,248

(81,417)

Opening net debt/(cash)

 

 

(43,883)

(50,783)

(161,632)

(99,375)

(116,623)

Other

 

 

0

(16)

(17)

0

0

Closing net debt/(cash)

 

 

(50,783)

(161,632)

(99,375)

(116,623)

(35,207)

Source: Edison Investment Research, Imperial Innovations accounts. Note: Edison’s EBITDA and PBT normalised figures exclude net fair value gains/losses.

Contact details

Revenue by geography

52 Princes Gate

Exhibition Road
London SW7 2PG
+44 (0)20 7581 4949
www.imperialinnovations.co.uk

N/A

Contact details

52 Princes Gate

Exhibition Road
London SW7 2PG
+44 (0)20 7581 4949
www.imperialinnovations.co.uk

Revenue by geography

N/A

Management team

CEO: Russ Cummings

Chief investment officer: Nigel Pitchford

CEO since July 2013, having been CIO and director since 2006. NED of portfolio companies Circassia (since 2007) and Nexeon (since 2007). Previously with Scottish Equity Partners (2004-06) and 3i Group (1987-2003). Member of the British Venture Capital Association (BVCA) Venture Capital Committee. BSc in mechanical engineering from Imperial College London.

CIO since October 2013, having held the position of MD Healthcare Investments since 2012. NED of portfolio companies Oxford Immunotec, Polytherics, Veryan Medical, Psychology Online and E3Bio. Previously a partner at DFJ Espirit (2009-11) and 3i (1997-2009). MA in chemistry from the University of Oxford, PhD from University of Durham, MBA from Warwick Business School.

MD, technology transfer: Tony Hickson

Treasury and finance director: Anjum Ahmed

MD since October 2013, having joined Innovations in 2002. Experience includes over 16 years in various commercial IP and licensing roles at bioscience companies including Wellcome Group R&D, Murex Biotech, Abbott Laboratories and Kalibrant Limited. Previously board director or observer for a number of start-up companies including Emcision, Polytherics, Acublate and Respivert. Chairman of the Intellectual Property Board for the European Climate Change KIC and a Certified Licensing Professional.

FD since April 2013, having been group financial controller for 10 years. Previously FD of a venture capital backed start up as well as having held senior finance roles at GlaxoSmithKline, BBC Worldwide and the British Red Cross. Fellow of the Association of Chartered Certified Accountants; holds a treasury qualification and an MBA.

Management team

CEO: Russ Cummings

CEO since July 2013, having been CIO and director since 2006. NED of portfolio companies Circassia (since 2007) and Nexeon (since 2007). Previously with Scottish Equity Partners (2004-06) and 3i Group (1987-2003). Member of the British Venture Capital Association (BVCA) Venture Capital Committee. BSc in mechanical engineering from Imperial College London.

Chief investment officer: Nigel Pitchford

CIO since October 2013, having held the position of MD Healthcare Investments since 2012. NED of portfolio companies Oxford Immunotec, Polytherics, Veryan Medical, Psychology Online and E3Bio. Previously a partner at DFJ Espirit (2009-11) and 3i (1997-2009). MA in chemistry from the University of Oxford, PhD from University of Durham, MBA from Warwick Business School.

MD, technology transfer: Tony Hickson

MD since October 2013, having joined Innovations in 2002. Experience includes over 16 years in various commercial IP and licensing roles at bioscience companies including Wellcome Group R&D, Murex Biotech, Abbott Laboratories and Kalibrant Limited. Previously board director or observer for a number of start-up companies including Emcision, Polytherics, Acublate and Respivert. Chairman of the Intellectual Property Board for the European Climate Change KIC and a Certified Licensing Professional.

Treasury and finance director: Anjum Ahmed

FD since April 2013, having been group financial controller for 10 years. Previously FD of a venture capital backed start up as well as having held senior finance roles at GlaxoSmithKline, BBC Worldwide and the British Red Cross. Fellow of the Association of Chartered Certified Accountants; holds a treasury qualification and an MBA.

Principal shareholders

(%)

Invesco Asset Management

39.8

Woodford Investment Management

20.0

Imperial College London

17.4

Lansdowne Partners

12.9

Companies named in this report

AstraZeneca (AZN), CellMedica, Circassia (CIR), Covestro (1COV), Econic Technologies, Eli Lilly (LLY), FeatureSpace, GlaxoSmithKline (GSK), Kesios Therapeutics, Mission Therapeutics, Nexeon, Novomer, PsiOxus Therapeutics, Sony (SNE), Stryker (SYK), Tesla Motors (TSLA).

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER
Copyright 2016 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Imperial Innovations and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2016. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Share this with friends and colleagues